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Abstract
Background: Provoked vestibulodynia is the most common form of vulvodynia. Despite its high prevalence and
deleterious sexual, conjugal, and psychological repercussions, effective evidence-based interventions for provoked
vestibulodynia remain limited. For a high proportion of women, significant pain persists despite the currently
available treatments. Growing evidence suggests that the central nervous system (CNS) could play a key role in
provoked vestibulodynia; thus, treatment targeting the CNS, rather than localized dysfunctions, may be beneficial
for women suffering from provoked vestibulodynia. In this study, we aim to build on the promising results of a
previous case report and evaluate whether transcranial direct-current stimulation, a non-invasive brain stimulation
technique targeting the CNS, could be an effective treatment option for women with provoked vestibulodynia.
Methods/design: This single-center, triple-blind, parallel group, randomized, controlled trial aims to compare the
efficacy of transcranial direct-current stimulation with sham transcranial direct-current stimulation in women with
provoked vestibulodynia. Forty women diagnosed with provoked vestibulodynia by a gynecologist, following a
standardized treatment protocol, are randomized to either active transcranial direct-current stimulation treatment
for ten sessions of 20 minutes at an intensity of 2 mA or sham transcranial direct-current stimulation over a 2-week
period. Outcome measures are collected at baseline, 2 weeks after treatment and at 3-month follow-up. The
primary outcome is pain during intercourse, assessed with a numerical rating scale. Secondary measurements focus
on the sexual function, vestibular pain sensitivity, psychological distress, treatment satisfaction, and the patient’s
global impression of change.
Discussion: To our knowledge, this study is the first randomized controlled trial to examine the efficacy of
transcranial direct-current stimulation in women with provoked vestibulodynia. Findings from this trial are expected
to provide significant information about a promising intervention targeting the centralization of pain in women
with provoked vestibulodynia.
Trial registration: Clinicaltrials.gov, NCT02543593. Registered on September 4, 2015.
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Background
Chronic vulvar pain represents a major health concern for
women. Vulvodynia is a highly neglected chronic pain con-
dition, affecting nearly 10 % of the female population [1].
Suspected to be the foremost cause of pre-menopausal
vulvodynia, provoked vestibulodynia (PVD) is characterized
by an acute recurrent pain located at the vulvar vestibule
(i.e., the vaginal entrance) in response to pressure applica-
tion or attempted vaginal penetration [2]. It has been re-
vealed that PVD disrupts personal lives, severely affects
sexual function, and negatively impacts the quality of life [3,
4]. PVD has also been related to relationship problems and
psychological distress [5]. Poorly understood and often mis-
diagnosed or ignored, PVD pain leads to a high personal
cost for patients and substantial financial cost for society.
Women with PVD often multiply their medical visits hop-
ing to find relief and rely mainly on non-evidence-based, in-
effective interventions [6].
Many empirical treatment options are proposed to
women with PVD. Firstly, localized interventions such as
topical lidocaine application [7], pelvic floor physical ther-
apy [8], biofeedback technique [9], Botox® injection [10],
topical use of estradiol and testosterone compounds [11],
and vestibulectomy (surgery) [12] can be offered. As a sec-
ond option, psychotherapeutic interventions can be pro-
posed, which include cognitive behavioral therapy (CBT)
focusing on reducing pain and improving sexual function
[13]; hypnotherapy [14]; or acupuncture [15]. In addition,
the use of systemic treatments, such as tricyclic antide-
pressants [16], anticonvulsant medication and selective
serotonin reuptake inhibitors (SSRIs) [17], can also be pre-
scribed. Despite this wide variety of treatment options, a
high proportion of women with PVD are refractory to
conventional treatments [12, 17, 18], highlighting the need
for novel approaches.
Recently, alterations in central pain mechanisms have
been suggested to play a key role in PVD, potentially
explaining the limited success obtained in some patients,
with treatments targeting the pain locally in the area of
the vestibule. Central sensitization has been observed in
many chronic pain conditions, including chronic pelvic
pain [19]. While the heightened sensitivity of peripheral
pain receptors following local trauma or infection usu-
ally resolves with time, in chronic pain, this hypersensi-
tivity is sustained and amplified by an extensive central
neural network that includes the spinal dorsal horn, lim-
bic system, and cortical structures [20]. Recent studies
suggest that the pathophysiology of PVD is not only lim-
ited to the vulvar vestibule but also involves central pain
processing alterations similarly to other chronic pain
conditions [21]. In support of such central alterations,
women with PVD have been shown to be more sensitive
in areas other than the genital regions compared to con-
trols (lower pain threshold) [21–23]. Moreover, imaging
studies have revealed increased activation of brain re-
gions associated with pain perception during painful
stimuli in women with PVD [24], a pattern of results
analogous to that observed in studies completed in other
chronic pain populations such as fibromyalgia [25–27],
irritable bowel syndrome [28–33], and idiopathic back
pain [34].
Imaging studies have also shown structural changes in
women suffering from PVD. Schweinhardt et al. [35] re-
vealed higher gray matter densities in pain modulatory
and stress-related areas in women with PVD, suggesting
potential alterations in the supraspinal pain modulatory
circuitry. These neuroanatomical changes in CNS re-
gions related to endogenous pain modulation could
explain the large-scale changes in pain sensitivity ob-
served in women with PVD (e.g., lower pain thresholds
in regions other than the vulvar vestibule). Another
argument in favor of central pain mechanism alterations
is the co-occurrence of other pain conditions such as
orofacial pain, fibromyalgia, and irritable bowel syn-
drome [4, 36]. Arnold et al. [4] found that women with
vulvar pain have a threefold to fourfold risk of having
these concomitant pain conditions. Furthermore, similar
medications (e.g., antidepressants) are commonly used
to treat PVD, fibromyalgia, and irritable bowel syn-
drome, suggesting that these disorders may share similar
pathophysiological mechanisms [37–39].
One proposed technique for modulating CNS activity
in chronic pain states is noninvasive brain stimulation
(NIBS). NIBS strategies aimed at modifying cortical
excitability for different purposes have emerged in re-
cent years [40]. Transcranial direct-current stimula-
tion (tDCS) is a specific form of NIBS that has been
shown effective for improving various chronic pain
conditions relating to spinal cord injury [41], fibro-
myalgia [42], multiple sclerosis [43], painful diabetic
polyneuropathy [44], pelvic pain [20, 45], and other
various syndromes such as trigeminal neuralgia, post-
stroke pain syndrome, and back pain [46]. tDCS is a
painless technique that consists of applying a low dir-
ect current through electrodes placed on the scalp to
target the cerebral cortex in order to modify cortical
excitability and reduce pain [40]. tDCS is a safe and
simple device and could be easily integrated into a re-
habilitation program.
Even if a large literature concerning tDCS in pain re-
lief now exists [40, 47, 48], to our knowledge, only one
case looking into the effect of tDCS in women with
vulvodynia [49] exists. In this case report, Cecilio et al.
describe the case of a woman suffering from severe
chronic vulvar pain refractory to many empirical treat-
ments (tricyclic antidepressants, anticonvulsants, and
opioid analgesics) who has experienced remarkable
long-lasting pain relief with tDCS. On the basis of the
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pathophysiology of chronic pain related to PVD that is
similar to other chronic pain syndromes, and consid-
ering that it is a neglected women’s health condition,
we believe it is important to study the efficacy of this
promising treatment in women with PVD. The main
goal of this study is to evaluate the efficacy of active tDCS
treatment in women with PVD compared to sham tDCS
for pain during intercourse, as assessed with a numerical
rating scale. We expect that active tDCS treatment will
significantly reduce pain during intercourse (2-week post-
treatment and 3-month follow-up compared to the pre-
treatment assessment). We expect that active tDCS
treatment will be more effective for reducing pain than
the sham tDCS treatment at 2-week post-treatment and
3-month follow-up.
Secondary objectives are to compare the efficacy of
active tDCS vs. sham tDCS on sexual function, sexual
satisfaction, vestibular pressure-pain threshold, psycho-
logical distress (catastrophizing, anxiety, depression, fear
of pain, and vaginal penetration cognition), treatment
satisfaction, and patient global impression of change (2-
week post-treatment and 3-month follow-up compared
to pretreatment assessment).
Methods/design
Design
The proposed research design is a triple-blind (physiother-
apist assessor, patient, and treatment provider), random-
ized, placebo-controlled, parallel-group trial. Participants
are randomized to receive either active or sham tDCS for
ten sessions of 20 minutes of stimulation over a 2-week
period. As illustrated in the flow diagram (Fig. 1), the study
includes three evaluation points (pretreatment assessment,
post-treatment assessment performed at 2 weeks, and
follow-up assessment at 3-months post-treatment). This
study protocol was written in accordance with the SPIRIT
statement (see Additional file 1 for the completed SPIRIT
checklist).
Participants
Premenopausal women, ages 18–45 years, suffering from
pain during intercourse, are being recruited at the Re-
search Center of the Centre Hospitalier Universitaire de
Sherbrooke (CHUS). The eligibility criteria are detailed
in Table 1. These criteria were selected to ensure recruit-
ment of a homogenous sample of sexually active women
with PVD and were based on previous successful studies
Fig. 1 Study flow diagram
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[13, 50, 51]. In order to confirm the diagnosis of PVD,
the eligibility screening comprises a gynecological assess-
ment performed by a gynecologist from our team, fol-
lowing a standardized protocol. The latter consists of a
brief anamnesis and a comprehensive gynecological exam-
ination of the vulvar region (clitoris, small lips, interlabial
furrow, and vestibule), testing for vaginal infection and
sexually transmitted disease, and palpation of the uterus
and appendices. This evaluation follows the diagnostic cri-
teria defined by Friedrich [2] and more recently modified
by Bergeron et al. [52], namely, (1) pain in the vestibule fol-
lowing touch or an attempted vaginal penetration or (2)
acute pain during palpation of the vestibule region with a
cotton swab. Interevaluator fidelity of this diagnosis method
has been demonstrated [52] and used in several RCTs
[13, 53, 54]. Therefore, vulvar pain occurring in the ab-
sence of an underlying recognizable disease and pro-
voked spontaneously as a result of physical contact can
be classified as PVD [55].
Treatments
Participants are randomized to receive ten sessions of
either active or sham anodal tDCS over a period of
14 days. tDCS treatments are given once a day, during
weekdays (Monday to Friday). Each session lasts 20 minutes
[20, 41, 44, 56, 57] and is administered by a research profes-
sional experienced in tDCS. The treatment provider is not
involved in the patient assessment and is blinded to the
treatment allocation by selecting a preset program of the
tDCS device (NeuroConn DC stimulator). Two electrodes
are applied to the subject’s scalp; the anode is placed over
the motor cortex (M1) [58], and the cathode, over the
contralateral supraorbital area [20, 41, 44, 57, 58]. For
treatment with active tDCS, the intensity of the stimu-
lation is set at 2 mA for the entire duration of the
treatment [20, 41, 42, 44, 49, 56]. The parameters used
in our study have been tested with many subjects in
several different laboratories without side effects [59],
apart from a slight itching, tingling, or burning sensa-
tion under the electrode during the first seconds of
stimulation; discomfort or erythema (skin reddening)
under the active electrode; and possible headache in
the hours following the treatment. If the stimulation is
switched on or off abruptly, the sensation of a short
ocular light flash could also be felt by the participant
[60]. For subjects receiving sham tDCS (placebo group),
the electrodes are positioned in the same areas as the
group receiving active stimulation, and the intensity is set
at 2 mA for the first 30 seconds of treatment [57], after
which the stimulation stops automatically. Just as for ac-
tive tDCS, participants are advised that a brief tingling
sensation may be felt at the beginning of treatment. This
method is effective for preserving subject and investigator
blinding [61].
In order to report the participants’ adverse events during
tDCS treatment, at each treatment session, the treatment
provider notes the participants’ side effects, and the subjects
are asked to complete a logbook in which they have to
report whether they experience any adverse events or pain
in the vulvar region, whether related to intercourse or not.
Participants also have to record their experienced vulvar
pain in the same logbook between the end-of-treatment
period and the 2-week post-treatment assessment.
Recruitment and procedures
Participants are recruited using different promotion strat-
egies: (1) referrals from health professionals (gynecologist,
general practitioner, sexologist, psychologist, or physiother-
apist); (2) posters and leaflets distributed to women in
clinics, universities, professional schools, restaurants, gyms,
etc.; (3) Facebook advertisement; and 4) advertisements in
local newspapers. Women interested in participating are in-
vited to contact the research coordinator for a detailed
explanation of the study and verification of their eligibility.
Thereafter, participants undergo a gynecologist’s examin-
ation for confirmation of their diagnoses. Once a diagnosis
of PVD has been confirmed, the research assistant contacts
the participants to confirm their admissibility into the
study. Upon doing so, she provides the participants with in-
structions to follow before the assessment and, then, fixes
the appointments. To avoid effects on the vestibular pain
sensitivity measurements prior to each assessment, partici-
pants will be asked to refrain from smoking and consuming
caffeine (coffee, tea, and energy drinks) 4 hours prior to the
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
- Experience moderate to severe pain (minimum of 5/10
on a numerical rating scale (NRS)) in at least 90 % of attempted
sexual intercourse
- Pain limited to the vestibule during vaginal intercourse and during
activities exerting pressure on the vestibule (tampon insertion, tight
jeans or pants, cycling, horseback riding)
- Presence of provoked vestibulodynia (PVD) for at least 6 months and
diagnosed according to the standardized gynecological examination
protocol by one of our staff gynecologists
- Have a stable sexual partner (sexual activity should include some
attempted vaginal penetrations in order to evaluate pain intensity)
- Urogynecological conditions (e.g., active urinary tract or vaginal infection
or in the last 3 months, etc.) and other pelvic pathology associated
with pelvic pain (e.g., deep dyspareunia)
- Have given birth in the last year and breast feeding
- Anterior vulvar or vaginal surgery
- Refusal to refrain from other treatments 1 month prior to first treatment
study until the last 3-month follow-up assessment
- Contraindications to transcranial direct-current stimulation (tDCS)
(e.g., metallic implant in or near the skull, history of epilepsy, pacemaker)
- Previously received tDCS treatment
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evaluation [62], to refrain from taking painkillers (Advil®,
Motrin®, Tylenol®, etc.) 24 hours before the evaluation [63],
and to not have or attempt vaginal intercourse in the
24 hours before the evaluation [64]. After signing the
informed consent, the eligible women are invited to
undertake a 1-hour pretreatment assessment (baseline)
with a physiotherapist specialized in pelvic-floor re-
habilitation and pain assessment. During the pretreat-
ment assessment, a structured interview is conducted to
collect the patient’s baseline characteristics, and standard-
ized questionnaires are completed. Approximately 30 mi-
nutes are required to complete all questionnaires. These
questionnaires have been successfully used in our previous
studies, without hindering data quality [65]. A vestibular
pain sensitivity assessment is also undertaken using the alg-
ometer [66]. The participants are then randomized to re-
ceive either active or sham tDCS. The same procedures are
repeated at the 2-week post-treatment and 3-month follow-
up assessments.
Participant retention and protocol adherence
As for other clinical trials, the greatest challenges pertain to
participant retention. Strategies implemented to minimize
attrition are as follows: (1) each participant is required to
supply her contact information, such as phone number(s)
and e-mail address; 2) a research assistant makes sure to re-
mind participants of their appointments, as well as of the
importance of their continuous participation; 3) all appoint-
ments are flexible to fit in with the participants’ schedule
(i.e., early morning, late in the evening, etc.); and 4) partici-
pants receive a $20 compensation at three different stages
of the study (the assessments) to cover travel expenses and
their participation in the study. Adherence to the study
protocol is also promoted throughout the trial. The
physiotherapist-evaluator has received a standardized train-
ing to ensure homogeneity of procedures and reduce bias
due to the evaluator. This physiotherapist-evaluator also
has access to a detailed written assessment protocol Ver-
sion 4 (Nov. 2, 2015). The research professional in charge
of treatment is not involved in patient assessment and simi-
larly has received proper training for the application of
tDCS. The PI also carries out a weekly supervision of the
physiotherapist’s and professional’s adherence to protocols.
Moreover, the effectiveness of blinding for all physiothera-
pists and patients is evaluated with a questionnaire. Partici-
pants are also asked to abstain from the following PVD-
related treatments (i.e., pelvic floor physical therapy, topical
lidocaine application, vestibulectomy, and psychothera-
peutic and systemic interventions) during their enrollment
in the study, and this is monitored at the 2-week post-
treatment and 3-month follow-up assessments. In order to
avoid missing data, at the end of each assessment, the
physiotherapist-evaluator revises all completed question-
naires before the participant leaves.
Randomization and blinding
After the pretreatment assessment, the participants are
randomized into either the active or sham tDCS treatment
(ratio 1:1) using permuted blocks of two and four. The
allocation is managed by an individual independent
from our research team who follows a computer-generated
randomization list drawn up by an independent statistician.
Participants, investigators, physiotherapist assessors, and
the treatment provider remain blinded to group allocation
and, therefore, cannot influence the process in any way.
Outcomes
The Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) has recently recom-
mended several outcome domains for use in evaluating the
effectiveness of treatment in chronic pain conditions [67].
The current protocol adheres to these recommendations,
with outcomes focusing on the multiple dimensions of
PVD, such as pain, sexual function, psychological distress,
participant ratings of improvement and satisfaction with
treatment, and the need to assess the potential impact of
treatment on these different dimensions.
Primary outcome measure
As recommended by the IMMPACT [67, 68], participants
are asked to evaluate their pain during intercourse with an
NRS, 0 indicating no pain, and 10, the worst pain ever ex-
perienced. This scale has been frequently used in women
with PVD [13, 69–71] and shows good reliability, validity,
and responsiveness to change [13, 52, 69–71].
Secondary outcome measure
Pain measurements Different measurements of pain
are recommended by the IMMPACT consensus group in
order to evaluate different domains of pain [67, 72]. Ran-
ging from 0 to 74, the McGill-Melzack questionnaire is
a 20-item scale allowing the assessment of pain quality
(i.e., sensory, affective, and evaluative components). A
higher total score is related to more severe pain. This
world-renowned questionnaire, studied for its validity,
reliability, and responsiveness to change, is commonly
used in RCTs [13, 52, 73–78].
Furthermore, the third International Consultation on
Sexual Medicine has emphasized the importance of asses-
sing vestibular sensitivity [79]. Our laboratory recently
developed an algometer to measure the vulvar pain thresh-
old and tolerance in women with PVD. A gradual pressure
(1 to 1000 grams) is applied to three distinct points of the
vestibule at the 3, 6, and 9 o’clock positions [80]. Each of
these pressure points is applied randomly (e.g., 3,6,9 or
3,9,6 or 6,9,3). During this procedure, each participant is
asked to indicate when they start to feel pain (pain thresh-
old) and subsequently the maximal pressure they can
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tolerate (pain tolerance) (see [66] for more details). Pain
intensity is assessed throughout the test using a computer-
ized visual analog scale (CoVas). This assessment has
shown good reliability and validity [80].
Sexual function measurements The Female Sexual
Function Index (FSFI) is a 19-item multidimensional meas-
ure of sexual function evaluating desire, arousal, lubrication,
orgasm, satisfaction, and pain. This questionnaire is fre-
quently used in trials involving women with PVD [13, 78].
In addition to good psychometric properties (reliability,
internal consistency, and responsiveness to change) [8, 81],
normative data are available for this questionnaire, suggest-
ing clinical levels of dysfunctions [82]. Women considered
at risk for sexual dysfunction record a FSFI total score of 26
or less [82].
In order to measure the participant’s sexual satisfac-
tion, the Global Measure of Sexual Satisfaction (GMSS)
questionnaire is used. This five-item questionnaire has a
total score ranging from 5 to 35 and presents good psy-
chometric properties (a high level of internal consistency
and test-retest reliability) [83]. Better sexual satisfaction
will result in a higher total score. Inclusion of these
questionnaires is in line with the recommendations of
the IMMPACT consensus group [67] recommending
evaluation of the impact of pain on functions.
Psychological distress Many studies have also deter-
mined that vulvodynia may even be a source of psycho-
logical distress [5, 84]. For these important reasons,
different psychological variables are evaluated.
The Pain Catastrophizing Scale (PCS) is a 13-item
questionnaire with good reliability, consistency, and
responsiveness [8, 85] for evaluating the level of pain
catastrophization, a robust predictor of pain and incap-
acity. The PCS yields a total score (0–52) and three
subscale scores assessing rumination (0–16), magnifica-
tion (0–12), and helplessness (0–24). Research at the
University Centre for Research on Pain and Disability
indicates that a total PCS score of 30 represents a clinic-
ally relevant level of catastrophizing [86].
The State-Trait Anxiety Inventory of Spielberger
(STAI-Y) allows discrimination between anxiety as a trait
of personality (T-Anxiety) or as an emotional response
to a situation (S-Anxiety) [87]. This 40-item question-
naire, in which 20 items are allocated to each of the S-
Anxiety and T-Anxiety subscales, has previously been used
in women with PVD [78] and has shown a good reliability,
consistency, and responsiveness [8, 87]. Responses for the
S-anxiety scale assess intensity of current feelings “at this
moment” according to the following: (1) not at all, (2)
somewhat, (3) moderately so, and (4) very much so.
Responses for the T-anxiety scale assess frequency of feel-
ings “in general” according to the following: (1) almost
never, (2) sometimes, (3) often, and (4) almost always [88].
Although this questionnaire was not designed or validated
to be used with a cut-off score, an earlier Hungarian
research used T-anxiety cut-off values as follows: less than
48 indicating no anxiety, 48 to 52 indicating mild or sub-
clinical disorder, and higher than 52 indicating significant
anxiety [89].
The Beck Depression Inventory questionnaire (BDI)
[90] was recommended by Dworkin et al. [67] for asses-
sing depression [91]. This scale has been studied for its
reliability and consistency [91] and has also been used in
women with PVD [78]. This 21-item questionnaire has a
total score ranging from 0 to 63. Higher total scores indi-
cate more severe depressive symptoms. Total score cut-
offs for this questionnaire are as follows: 0–9 indicating
that a person is not depressed, 10–18 indicating mild-
moderate depression, 19–29 indicating moderate-severe
depression, and 30–63 signifying severe depression [90].
The Pain Anxiety Symptoms Scale (PASS-20), which
evaluates four distinct components of pain-related anxiety
(i.e., cognitive, fear, escape/avoidance, and physiological),
also shows good psychometric properties [92, 93]. The
total score of this 20-item questionnaire ranges from 0 to
100. A higher total score is related to higher levels of pain-
related anxiety. Individuals with acute pain presenting a
total score exceeding 30 may be at an elevated risk for
maladaptive pain cognitions and behaviors promoting
chronic pain and disability [94].
Satisfaction with treatment and the Patient’s Global
Impression of Change The dimension of patient’s global
impression of change (PGIC) is also evaluated [95, 96].
PGIC is a validated questionnaire [97] through which pa-
tients self-report selected measures to evaluate perceived
reduction in pain using a seven-point scale ranging from
“very much improved” to “very much worse” and rate their
treatment satisfaction over an 11-point scale that ranges
from “completely satisfied” to “completely dissatisfied” in
order to assess the clinical significance of the results. Sub-
jective evaluations of pain improvement and treatment
satisfaction have previously been evaluated in a random-
ized trial involving women with PVD [13].
Ethical aspects
The study has received ethical approval from the comité
d’éthique de la recherche en santé chez l’humain du
CHUS (14-169). Every potential participant is made aware
that there will be no impact on her medical care if she
decides not to participate in the study. Women who refuse
to participate in the study or who do not fulfill the eligibil-
ity criteria are followed by the clinical staff using the most
recently proposed vulvodynia guidelines. In order to
minimize privacy risks, all participants are identified by an
alpha-numeric code. Informed consent is obtained from
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all participants prior to trial inclusion. This trial is regis-
tered at clinicaltrials.gov NCT02543593.
Statistical considerations
Sample size, power, and statistical analysis methods
A total sample size of 34 participants is sufficient to de-
tect a clinical minimal significant difference of 2 [67, 98]
on an NRS (unpaired t test; α = 0.05; β = 0.80, standard
deviation of 2.0) based on the efficacy of tDCS in other
painful conditions [57, 99]. This estimation is conserva-
tive considering that tDCS in chronic pain demonstrated
a mean pain reduction of 4.34 points [40] and that the
available case study in a woman with vulvodynia showed
a reduction of ten points [49]. To account for potential
dropouts, a total of 40 subjects are being recruited. This
estimated dropout rate (< 15 %) is based on available
studies and our own RCT experience in women with
PVD [13, 78, 100].
Statistical analyses
Baseline characteristics of the sample will be presented
using descriptive statistics. Analyses will be done on the
intention-to-treat basis. Parametric test assumptions will
be examined and reported. If the data is not normally
distributed, nonparametric data will be transformed. The
effects of treatment on pain, sexual function and psycho-
logical distress will be examined using a mixed linear
model for repeated measures. One of the factors will be
the GROUP, at two levels (the treatment group receives
active tDCS, and the control group, sham tDCS), while
the repeated factor will be TIME (baseline, 2-week
post-treatment, and 3-month follow-up assessments).
Treatment efficacy will be judged on the basis of a signifi-
cant GROUP*TIME interaction and contrast analysis (i.e.,
Tukey-Kramer contrasts when using a mixed-model ap-
proach) [101] to detect any differences. The difference be-
tween the two groups regarding satisfaction and PGIC will
also be assessed using a mixed linear model for repeated
measures. However, the baseline assessment will not be a
repeated time-factor for these analyses. All statistical ana-
lyses will be conducted at a level of significance of 0.05.
Sensitivity analyses will be conducted to explore the effect
of multiple imputation methods to replace missing data.
The non-robustness of our results due to missing value
will be noted and discussed.
Discussion
This is the first study to evaluate the efficacy of tDCS for
reducing pain during intercourse in women with PVD.
Considering that the current literature on PVD patho-
physiology has converged toward the cause being central
pain sensitization, tDCS is a promising treatment target-
ing central mechanisms rather than focusing strictly on
the vestibule.
The plausibility of treatment effects relies on a large
body of evidence supporting treatment efficacy in vari-
ous chronic pain conditions [40], including a case study
showing complete pain resolution in a woman with vul-
vodynia [49]. The underlying mechanisms of action also
support the potential short and long-lasting effects in
women with PVD. Immediate effects of tDCS are ex-
plained by polarity-dependent shifts of the resting mem-
brane potential and consequent alteration of corticospinal
excitability at the stimulation site. Alteration leads to fa-
cilitation or inhibition of the superficial structures and of
deeper and more remote brain areas related to pain
modulation, such as the periaqueducal gray, insula, and
thalamus [40]. Thus, the immediate effects of tDCS are
a consequence of neuronal hyperexcitability caused by
the anode or hypoexcitability induced by the cathode
[47], whereas the long-lasting effects of tDCS seem to
depend on N-methyl-D-aspartate (NMDA) receptor-
efficacy changes [102]. In patients with chronic pain,
the anode is commonly placed over the motor cortex
(M1) [103]. According to functional imaging studies,
stimulation of the motor cortex modulates activity in
the limbic system, brainstem and spinal cord, which are all
involved in the emotional component of pain [104–106].
Therefore, even if the genital zone is located deeper in the
central sulcus of the somato-sensorial cortex, available evi-
dence suggests that the mechanism of action of tDCS for
reducing pain involves the emotional component of pain.
This randomized placebo-controlled trial addresses the
urgent need to provide evidence-based treatments for
women with PVD. In addition, blinding of participants,
evaluators, and investigators, as well as the use of rec-
ommended validated tools, strengthened our study design.
Given the efficacy found in various chronic pain condi-
tions and the promising results obtained in a case report
study in a woman with vulvodynia, this new treatment
avenue may give hope to women who have experienced
failure with the available localized treatments.
Trial status
The recruitment of participants is ongoing at the Research
Center of the CHUS. Forty women with PVD are planned
to be recruited and randomized from December 2014 to
May 2016.
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